ClinicalTrials.gg
CompletedNCT00654017Updated Feb 1, 2021

A Study Evaluating the Efficacy and Safety of Sildenafil in Patients With Erectile Dysfunction Receiving Hemodialysis

A Phase 4 interventional study of placebo and sildenafil in Erectile Disfunction and Hemodialysis, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 8 sites in Brazil. Open to male participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2021-02-01.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
19 Years and older
Sex
Male
01

Study summary

The study was done to evaluate the efficacy, safety, and tolerability of orally administered sildenafil taken as needed about one hour before sexual activity after a 10-week period in male outpatients with erectile dysfunction and severe renal failure who were on hemodialysis.

02

Conditions studied

  • Erectile Disfunction
  • Hemodialysis
03

In context

Lead sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.

First submitted before Pfizer's Upjohn has merged with Mylan to form Viatris Inc. became part of Viatris Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Included patients had been in a stable relationship with a female partner for at least 6 months
  • A diagnosis of renal failure, with ≤10 ml/min; been under hemodialysis for at least 6 months prior to the screening period, and a clinical diagnosis of erectile dysfunction (ED) as confirmed by International Index of Erectile Function (IIEF-5) score of \<21 and defined as an "incapacity to obtain and/or maintain an erection sufficient for a satisfactory sexual performance".

Exclusion criteria

Exclusion Criteria:

  • Patients in regular use of nitrates or nitric oxide donor drugs, or have received a prescription to use these substances in any formulation
  • Patients with genital anatomic malformation that may significantly impair erection (e.g., serious penile fibrosis)
  • Patients with other sexual disorders (e.g., hypoactive sexual desire) considered as a primary diagnosis, with a coexisting ED diagnosis, including patients receiving anti-androgenic therapy whose libido has not been preserved; patients receiving hormonal replacement therapy for at least 6 months, or whose dose has not been stabilized within the last 6 months before the study screening period
  • Patients with diabetes mellitus presenting poor control of their diabetes and/or proliferate diabetes retinopathy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (estimated)

Study arms

  • Placebo comparator
    placebo

    Drug: placebo

  • Active comparator
    sildenafil

    Drug: sildenafil

Interventions

  • Drugplacebo

    Placebo comparator to be given per protocol.

  • oral sildenafil citrate at an initial dose of 25 mg, which could have been up-titrated to 50 mg at Visit 3 based on the patient's efficacy, safety and tolerability responses; at Visits 4 and 5, the dose could remain the same, be increased to 100 mg, or decreased to 25 mg depending on the safety, efficacy, and tolerability

06

What researchers measure

Primary outcomes

  1. Response to questions 3 (frequency of penetration) and 4 (frequency of maintained erection) of the International Index of Erectile Function (IIEF).

    Time frame: Baseline and Week 10

Secondary outcomes

  1. rate of successful sexual intercourse (number of attempts at sexual intercourse, number of successful attempts and percentage of attempts that were successful)

    Time frame: Baseline to Week 10

  2. response to Partner's Satisfaction Questionnaire (optional)

    Time frame: Week 10

  3. total Score of Quality of Life and erectile dysfunction questionnaire

    Time frame: Baseline and Week 10

  4. monitoring of adverse events (AEs) and measurement of sitting blood pressure and heart rate

    Time frame: Baseline, and Weeks 2, 4, 6, and 10

  5. response to Question 1 of the Global Efficacy Assessment Question

    Time frame: Week 10

  6. responses to questions of the IIEF

    Time frame: Baseline and Week 10

07

Study locations

8 sites
  • Pfizer Investigational Site
    Fortaleza, CE 60430-370, Brazil
  • Pfizer Investigational Site
    Belo Horizonte, MG 30150-260, Brazil
  • Pfizer Investigational Site
    Belo Horizonte, Minas Gerais, Brazil
  • Pfizer Investigational Site
    Londrina, PR 86010-010, Brazil
  • Pfizer Investigational Site
    JAU, SAO Paulo 17210-080, Brazil
  • Pfizer Investigational Site
    Sorocaba, São Paulo 18030-205, Brazil
  • Pfizer Investigational Site
    São José do Rio Preto, São Paulo, Brazil
  • Pfizer Investigational Site
    Sao Paulo, 01323-001, Brazil
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2002 and a completion of Apr 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2008
First posted
Apr 7, 2008
Start
Oct 2002
CompletionActual
Apr 2005
Last update
Feb 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00654017
Responsible party
Sponsor
First posted
Apr 7, 2008
Start date
Oct 2002
Completion
Apr 2005
Last update
Feb 1, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion